Pembrolizumab plus high-dose IL-2 in advanced clear cell renal cell carcinoma: six-year survival outcomes and molecular signatures from a phase 2 trial

Journal:

Nature Communications

Published:

2026-05-25

DOI:

10.1038/s41467-026-73336-1

Affiliations:

9

Authors:

24

Go to article

Institutions	Authors	Share
H. Lee Moffitt Cancer Center & Research Institute, United States of America (USA)	20.000000 20.000000 20.000000	0.83
USF Health, United States of America (USA)	1.500000	0.06
Weill Cornell Medicine, United States of America (USA)	1.000000	0.04
Orlando Health, United States of America (USA)	1.000000	0.04
Tampa General Hospital (TGH), United States of America (USA)	0.500000	0.02

Interested in Oncology and Carcinogenesis?